Quaker Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Quaker Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.66K	Hold	7	–	–	﹤0.01%	373
2026 Q2	$3.48K	Sell	7 -43	-86%	-$19.1K	﹤0.01%	382
2026 Q1	$22.3K	Buy	50 +2	+4%	+$933	0.01%	242
2025 Q4	$21.8K	Buy	48 +1	+2%	+$431	0.01%	247
2025 Q3	$18.4K	Sell	47 -1	-2%	-$418	0.01%	240
2025 Q2	$21.4K	Buy	+48	New	+$22.1K	0.01%	243

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Quaker Wealth Management's VRTX Position: Q3 2026 in Review

Quaker Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 7 shares worth $3.66K. The position accounts for ﹤0.01% of the portfolio, ranked #373.

Quaker Wealth Management first reported a position in VRTX in Q2 2025 and has held it in 6 quarters since. The position peaked at $22.3K in Q1 2026. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Quaker Wealth Management held 7 shares of Vertex Pharmaceuticals worth $3.66K as of Q3 2026.
Quaker Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Quaker Wealth Management's portfolio in Q3 2026, its #373 holding.
Quaker Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Quaker Wealth Management's Vertex Pharmaceuticals position peaked at $22.3K in Q1 2026.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Quaker Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.